BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC

Ignatov, T. and Poehlmann, A. and Ignatov, A. and Schinlauer, A. and Costa, S. D. and Roessner, A. and Kalinski, T. and Bischoff, J. (2013) BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC. BREAST CANCER RESEARCH AND TREATMENT, 141 (2). pp. 205-212. ISSN 0167-6806,

Full text not available from this repository. (Request a copy)

Abstract

The aim of the current study was to investigate the role of BRCA1 gene aberrations in sporadic triple-negative breast cancer (TNBC) and its impact on anthracycline-based therapy. BRCA1 promoter methylation was analyzed in 70 TNBC and compared with the clinical and pathologic characteristics. As a control group, we used 70 patients with non-TNBC. BRCA1 promoter methylation was observed in 65.2 % of patients and was similar in both groups. BRCA1 promoter methylation was associated with decreased intensity of BRCA1 protein expression (P = 0.002) and significant increase of median disease-free survival (DFS) of TNBC patients receiving adjuvant anthracycline-based chemotherapy (P = 0.001). Multivariate analysis revealed that BRCA1 promoter methylation remains a favorable factor in regard to DFS (HR 0.224; 95 % CI 0.092-0.546, P = 0.001) in TNBC after adjustment for other prognostic factors. In contrast, in non-TNBC, BRCA1 promoter methylation was not associated with any clinical and pathologic parameters. BRCA1 promoter methylation is a common mechanism of BRCA1 gene aberration in sporadic breast cancer and is predictive for better response to anthracycline-based therapies.

Item Type: Article
Uncontrolled Keywords: NEGATIVE BREAST-CANCER; RNA EXPRESSION LEVELS; NEOADJUVANT CHEMOTHERAPY; CHEMOSENSITIVITY; MUTATION; SENSITIVITY; CISPLATIN; TUMORS; CELLS; Breast cancer; BRCA1; Promoter methylation; TNBC
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Frauenheilkunde und Geburtshilfe (Schwerpunkt Frauenheilkunde)
Depositing User: Dr. Gernot Deinzer
Date Deposited: 01 Apr 2020 06:52
Last Modified: 01 Apr 2020 06:52
URI: https://pred.uni-regensburg.de/id/eprint/16118

Actions (login required)

View Item View Item